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Background: In contrast to other haematological cancers, mortality from non-Hodgkin’s lymphoma and multiple
myeloma increased dramatically during the second half of the 20th century in most developed countries. This
widespread upward trend remains controversial, as it may be attributable either to progressive improvements in
diagnosis and certification or to increasing exposures to little-known but relevant risk factors.
Methods: To assess the relative contribution of these factors, we analysed the independent effects of age, death
period, and birth cohort on haematological cancer mortality rates in Spain across the period 1952-2006. Weighted
joinpoint regression analyses were performed to detect and estimate changes in period and cohort curvatures.
Results: Although mortality rates were consistently higher among men, trends across periods and cohorts were virtually
identical in both sexes. There was an early period trend reversal in the 1960s for Hodgkin’s disease and leukaemia, which
was delayed to the 1980s for multiple myeloma and the 1990s for non-Hodgkin’s lymphoma. Birth cohort patterns
showed a first downturn for generations born in the 1900s and 1910s for all haematological cancers, and a second trend
reversal for more recent cohorts born in the 1950s and 1960s for non-Hodgkin’s lymphoma and leukaemia.
Conclusions: The sustained decline in Hodgkin’s disease mortality and the levelling off in leukaemia seem to be
driven by an early period effect linked to improvements in disease treatment, whereas the steep upward trends in
non-Hodgkin’s lymphoma and multiple myeloma mortality in Spain are more likely explained by a cohort effect
linked to better diagnosis and death certification in the elderly. The consistent male excess mortality across all
calendar periods and age groups points to the importance of possible sex-related genetic markers of susceptibility
in haematological cancers.
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improvementsBackground
Haematological malignancies constituted 6.9% of all inci-
dent cancer cases and 7.2% of all cancer deaths in Spain
in 2012 [1]. Morbidity and mortality from haemato-
logical cancers in Spain are fairly similar to the European
average [2], with age-adjusted incidence and mortality
rates of 2.4 cases and 0.3 deaths per 100,000 person-
years for Hodgkin’s disease, 10.0 cases and 3.3 deaths for
non-Hodgkin’s lymphoma (NHL), 3.5 cases and 2.2 deaths* Correspondence: rpastor@isciii.es
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this article, unless otherwise stated.for multiple myeloma, and 8.3 cases and 4.4 deaths for
leukaemia.
Since the mid-1970s, mortality from Hodgkin’s disease
and leukaemia declined steadily in most Western European
countries [3,4], a downward trend that was mainly attrib-
utable to substantial improvements in disease treatment.
In contrast, in the second half of the 20th century, there
was a dramatic increase in incidence and mortality from
NHL and multiple myeloma in many European countries
[3,5-7] and North America [8,9], which has only begun to
level off in recent years [10-13]. The reasons for this wide-
spread upward trend in developed countries are not fully
understood, since it may be largely artefactual due to thensee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly credited. The Creative Commons
ivecommons.org/publicdomain/zero/1.0/) applies to the data made available in
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techniques over recent decades, or it may partly reflect a
real increase in underlying incidence linked to changes in
environmental exposures to lymphomagenic agents and
other unknown risk factors. In addition, lymphoid tumours
have shown several problems of case ascertainment and
death certification from the beginning of cancer registry
activities, which further complicated the interpretation
of time trends in these haematological cancers [14].
Age-period-cohort models allow to disentangle the in-
dependent effects of age, death period, and birth cohort
on long-term time trends in cancer mortality, after con-
trolling for the potential confounding effects of the
remaining factors [15]. In particular, the identification of
significant trend changes in period and cohort effects
may help explain some features of the observed time
trends in haematological cancer mortality and assess the
relative contribution of both long-term exposure to risk
factors and recent improvements in diagnosis and treat-
ment. To this end, the present study sought to analyse
changes in period and cohort effects on haematological
cancer mortality in Spain across the period 1952-2006.
Methods
Data source
The number of deaths from Hodgkin’s disease, NHL, mul-
tiple myeloma, and leukaemia in Spain, broken down by
single calendar year, sex, and 5-year age group (0-4, 5-9, …,
80-84, and ≥ 85 years), was obtained from the Spanish Na-
tional Institute of Statistics for the period 1952-2006 [16].
The study period was restricted to 1962-2006 for multiple
myeloma, due to the reduced number of deaths from this
cause registered in Spain before 1962. Deaths from these
haematological cancers corresponded to different codes
from successive revisions of the International Classification
of Diseases (ICD) over the study period (Additional file 1:
Table S1). Haematological cancer death certification in
Spain has been shown to be accurate during the 1980s and
1990s, with detection and confirmation rates of 86% and
80% for lymphomas, 96% and 94% for multiple myeloma,
and 93% and 93% for leukaemia, as compared with clin-
ical and pathological reports [17]. Mid-year population
estimates for Spain were also obtained from the Spanish
National Institute of Statistics from 1952 to 2006 [16].
Statistical analysis
Age-adjusted mortality rates of haematological cancers
were calculated for each sex and 5-year calendar period
(1952-1956 to 2002-2006) using the direct method with
the European standard population. For each haemato-
logical cancer, age-adjusted male-to-female mortality rate
ratios and their 95% confidence intervals (CIs) were com-
puted for each 5-year period by assuming a Poisson distri-
bution for the observed number of deaths.To assess the effect of age, death period, and birth co-
hort on time trends in haematological cancer mortality in
Spain, log-linear Poisson models [18] were fitted to data
aggregated by 5-year age group and calendar period. The
open-ended group of persons aged 85 years or older was
excluded from these age-period-cohort analyses, as well as
those younger age groups having fewer than five deaths in
any 5-year calendar period. To overcome the problem of
non-identifiability of model parameters arising from the
exact linear dependence among age, period, and cohort,
we adopted the approach proposed by Holford [15,19]
and considered estimable functions of parameters, such as
the curvatures in each effect and the sum of period and
cohort linear slopes, also known as the net drift. Although
other solutions to the non-identifiability problem have
been proposed [15], the net drift and curvatures are
uniquely determined by the data and hence remain invari-
ant irrespective of the particular approach used. More spe-
cifically, the number of deaths from each haematological
cancer and sex dap registered at age a in period p was as-
sumed to follow a Poisson distribution with mean λapnap
and free dispersion parameter ϕ, where λap is the under-
lying mortality rate and nap is the number of person-years
at risk. The general form of the log-linear age-period-
cohort model for rates λap at age a in period p for persons
in birth cohort c = p – a was
log λap
  ¼ μþ αa þ βp þ γc;
where the intercept μ is the average log-rate over all age
groups and calendar periods, and the parameters αa, βp,
and γc represent the deviations from this overall log-rate
for age a, period p, and cohort c, whose respective aver-
ages (weighted by the corresponding marginal number
of person-years) are constrained to be 0. To address the
linear relationship between age, period, and cohort, each
temporal effect was further partitioned into linear and
curvature components [19,20]. The age effect was decom-
posed as αa ¼ αl a−awð Þ þ ~αa , where αl is the age slope,
aw is the average age index (weighted by the marginal
number of person-years by age group), and ~αa is the age
curvature with the linear trend removed. Applying similar
partitions to the period and cohort effects, the model was
reparameterized as
log λap
  ¼ μþ αl a−awð Þ þ ~αaf g
þ βl p−pwð Þ þ ~βp
n o




a−awð Þ þ βl þ γ l
 
p−pwð Þ þ ~αa
þ ~βp þ ~γ c;
since c−cw ¼ p−pwð Þ− a−awð Þ due to the linear de-
pendence among the three factors. All parameters of
this model are identifiable and hence have unique
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cused on the cross-sectional age effect for an average
period [20], which was obtained from the linear function
μþ αl−γl
 
a−awð Þ þ ~αa , the net drift or sum of period
and cohort linear slopes βl + γl, and the period and cohort
curvatures ~βp and ~γ c.
To detect and estimate changes in the period and cohort
effects of the three-factor model, separate joinpoint re-
gression analyses of the estimated period and cohort cur-
vatures ~βp and ~γ c were performed with weights inversely
proportional to their estimated variances vp and vc from
the above age-period-cohort model [21]. These joinpoint
models provided the number of significant change-points
across periods and cohorts by using permutation tests, the
estimate and 95% CI for the location of each change-
point, and the estimate and 95% CI for the difference in
annual percent changes (APCs) before and after each
change-point. Specifically, the joinpoint regression model
for the period curvature ~βp with a single significant
change-point τ was
~βp ¼ β0 þ β1pþ β2 p−τð Þþ þ ε;
where (p – τ)+ = p – τ if the period p is above the
change-point τ and 0 if p is below τ, and ε is the error
with mean 0 and heterogeneous variance vp [21]. To in-
terpret joinpoint regression coefficients, we added back
the period linear trend to the period curvature from the
above joinpoint model and obtained the two-segmented
period effect
βp ¼ βl p−pwð Þ þ ~βp
¼ β0 þ βl þ β1
 
pþ β2 p−τð Þþ þ ε;
where the intercept β0 ¼ β0−βlpw . The parameters βl +
β1 and βl + β1 + β2 represented the period slopes below
and above the change-point τ, respectively, which were
not estimable since the overall period slope βl cannot be
uniquely determined [19]. However, the change in period
slopes at the change-point can be estimated directly as
the coefficient β2 from joinpoint regression analysis of
period curvatures. Similar arguments can be applied to




Age-adjusted mortality rates of haematological cancers
were consistently higher among men than among
women over all 5-year periods, with male-to-female rate
ratios ranging from 1.65 to 2.17 for Hodgkin’s disease,
1.48 to 2.20 for NHL, 1.22 to 1.43 for multiple myeloma,
and 1.27 to 1.75 for leukaemia (Table 1). Time trends
were similar in both sexes, but differed substantially foreach haematological cancer (Figure 1). Hodgkin’s disease
mortality declined sharply after a short, initial upward
trend in the 1950s and 1960s (APCs in age-adjusted rates
over the entire study period of -2.3% in men and -1.8%
in women). However, mortality rates of NHL and mul-
tiple myeloma rose steeply throughout the 20th century
and attenuated only in recent years (overall APCs of
2.3% in men and 3.0% in women for NHL, and 3.6% in
both men and women for multiple myeloma). The initial
upward trend in leukaemia mortality gradually levelled
off and tended to decline as from the 1990s onwards
(overall APCs of -0.1% in men and -0.3% in women).Effect of age, death period, and birth cohort
The cross-sectional age effects on haematological cancer
mortality are displayed in Figure 2. The increasing age
trend in Hodgkin’s disease mortality rates showed a deflec-
tion at age 30, which was more marked in women than in
men. NHL and leukaemia mortality increased log-linearly
with age among middle-aged and older adults, with a
flat relation at younger ages for NHL and a J-shaped
trend for leukaemia. Mortality from multiple myeloma
also increased with age but showed a gradual deceleration
at older ages.
The curvatures in period effects, as well as the signifi-
cant period trend changes obtained from joinpoint re-
gression analyses, are shown in Figure 3 and Table 2.
Period curvatures for each haematological cancer were
virtually identical in both sexes. Hodgkin’s disease mortal-
ity experienced a sharp period trend reversal in the 1960s
(APC decreases of -6.3% in 1967 for men and -5.2% in
1965 for women), an early pattern that was also observed
to a lesser extent for leukaemia (APC decreases of -3.6%
and -4.4% in 1964 for men and women, respectively).
This favourable evolution in period trends was delayed
to the 1980s for multiple myeloma (APC decreases of -4.3%
in 1986 for men and -3.9% in 1987 for women) and to the
1990s for NHL (APC decreases of -3.3% and -3.5% in
1994 for men and women, respectively).
The curvatures and significant trend changes in cohort
effects are shown in Figure 4 and Table 2. Birth cohort
patterns were similar for both sexes and exhibited a first
downturn in mortality trends for generations born in the
first two decades of the 1900s, which was more marked
for multiple myeloma (APC decrease of -6.1% in both
sexes) than for the other haematological cancers (APC de-
creases of -4.3% to -2.3% in men and -5.1% to -3.5% in
women). A second, more recent trend reversal was also
detected for cohorts born in the 1950s and 1960s for NHL
(APC decreases of -4.9% for men born in 1968 and -2.3%
for women born in 1954) and leukaemia (APC decreases
of -2.5% for men born in 1964 and -2.8% for women born
in 1966).
Table 1 Age-adjusted mortality rates of haematological cancers in Spain (per 100,000 European standard population)
by sex and 5-year calendar period
1952–1956 1957–1961 1962–1966 1967–1971 1972–1976 1977–1981














Men 659 1.13 894 1.45 1,091 1.65 1,214 1.73 1,201 1.63 1,052 1.32
















Men 360 0.65 554 0.93 875 1.36 1,098 1.55 1,540 2.07 1,982 2.47
















Men 215 0.37 290 0.46 679 1.01 1,132 1.52












Men 1,592 2.63 2,435 3.77 3,128 4.50 3,648 4.93 4,224 5.56 4,927 6.06















1982–1986 1987–1991 1992–1996 1997–2001 2002–2006












Men 982 1.14 951 1.03 794 0.80 698 0.63 647 0.52














Men 2,736 3.19 3,992 4.30 5,046 5.00 5,957 5.29 6,272 4.97














Men 1,731 2.06 2,351 2.51 2,949 2.87 3,660 3.13 3,881 2.90














Men 5,881 6.75 6,562 7.03 7,132 7.03 7,748 6.86 8,547 6.67













1Age-adjusted mortality rate ratio of males to females and 95% confidence interval (CI).
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Figure 1 Age-adjusted mortality rates of haematological cancers (per 100,000 European standard population) by sex, Spain
1952-2006.
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Main findings
Our results show that, although mortality rates from
haematological malignancies were consistently higher
among men than among women throughout the ex-
tensive period studied, death period and birth cohort
patterns were virtually identical in both sexes. In the
case of period effects, the change-point at which mor-
tality attenuated was located in different calendar
years, depending on the cause of death. Hodgkin’s dis-
ease and leukaemia were the first tumours displaying
this attenuation in the 1960s, followed by multiple
myeloma in the 1980s and NHL in the 1990s. The
early period trend reversal for Hodgkin’s disease and
leukaemia was essentially attributable to substantial
improvements in the treatment of these haematologicaltumours, as has already been documented in other
European countries [3,4].
With respect to cohort effects, two findings should be
highlighted, namely, the homogeneous upward trends
for generations born before the 1920s for all four haem-
atological tumours and both sexes, and the similar
inverted U-shaped trends for NHL and leukaemia across
all birth cohorts. The widespread rises in earlier cohorts
suggest a phenomenon of progressive improvement and
subsequent saturation in the diagnosis and certification
of haematological tumours, particularly in the elderly. It
is also noteworthy that the decline in NHL mortality for
more recent generations occurred a decade later in men
than in women, since men born around 1960 were most
affected by the human immunodeficiency virus epidemic
derived from injection drug use.
Figure 2 Cross-sectional age effect on haematological cancer mortality rates by sex, Spain 1952-2006. The cross-sectional age effects for
an average period and their 95% confidence intervals (vertical bars) were obtained from the three-factor model with period-allocated drift and
period and cohort curvatures.
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Figure 3 Curvature in period effect on haematological cancer mortality rates by sex, Spain 1952-2006. The period curvatures and their
95% confidence intervals (vertical bars) were obtained from the three-factor model with the period linear slope removed. Significant trend
changes (connected solid segments) were obtained from weighted joinpoint regression analyses of period curvatures.
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Table 2 Changes in period and cohort effects on haematological cancer mortality rates by sex, Spain 1952-2006
Net drift1
Change in period effect2 Change in cohort effect3
Haematological
cancer
Year of death Difference in Birth year Difference in Birth year Difference in
(95% CI) (95% CI) APC (95% CI) (95% CI) APC (95% CI) (95% CI) APC (95% CI)
Hodgkin’s disease
Men -2.3 (-2.6 to -2.1) 1967.7 (1965.5–1972.5) -6.3 (-7.5 to -5.0) 1914.1 (1904.0–1919.0) -2.3 (-2.9 to -1.7) — —
Women -1.8 (-2.0 to -1.5) 1965.9 (1965.0–1968.0) -5.2 (-6.0 to -4.4) 1915.1 (1909.5–1919.0) -3.5 (-4.8 to -2.2) 1932.0 (1927.0–1976.5) 1.5 (0.2 to 2.9)
Non-Hodgkin’s lymphoma
Men 2.3 (2.0 to 2.5) 1994.5 (1990.0–NA) -3.3 (-5.1 to -1.5) 1919.9 (1915.0–1924.5) -3.6 (-4.1 to -3.1) 1968.7 (1962.0–1975.0) -4.9 (-6.2 to -3.6)
Women 3.0 (2.7 to 3.3) 1994.5 (1989.0–NA) -3.5 (-6.0 to -1.0) 1918.7 (1917.0–1920.5) -4.3 (-4.6 to -3.9) 1954.1 (1945.5–1962.0) -2.3 (-2.9 to -1.6)
Multiple myeloma
Men 3.6 (3.4 to 3.9) 1986.1 (1975.5–1994.0) -4.3 (-6.0 to -2.6) 1909.1 (1905.0–1911.5) -6.1 (-6.9 to -5.2) 1928.9 (1923.5–1936.5) -1.8 (-2.3 to -1.3)
Women 3.6 (3.2 to 3.9) 1987.0 (1975.0–1994.0) -3.9 (-5.7 to -2.0) 1905.4 (1902.5–1910.0) -6.1 (-7.8 to -4.5) 1924.7 (1922.0–1930.0) -2.9 (-3.5 to -2.3)
Leukaemia
Men -0.1 (-0.2 to 0.1) 1964.5 (NA–1969.5) -3.6 (-5.8 to -1.3) 1913.4 (1907.5–1916.5) -4.3 (-4.9 to -3.7) 1964.6 (1939.5–1973.0) -2.5 (-3.3 to -1.7)
Women -0.3 (-0.5 to -0.2) 1964.5 (NA–1967.0) -4.4 (-5.7 to -3.0) 1910.1 (1907.5–1915.5) -5.1 (-5.8 to -4.4) 1966.2 (1953.5–1972.5) -2.8 (-3.6 to -2.0)
1Overall annual percent change in age-adjusted mortality rates and 95% confidence interval (CI) obtained from the sum of period and cohort linear slopes from the three-factor model. 2Difference in annual percent
changes (APCs) before and after the estimated year of death with significant trend change as obtained from the weighted joinpoint regression analysis of period curvatures from the three-factor model. 3Differences in



















Figure 4 Curvature in cohort effect on haematological cancer mortality rates by sex, Spain 1952-2006. The cohort curvatures and their
95% confidence intervals (vertical bars) were obtained from the three-factor model with the cohort linear slope removed. Significant trend
changes (connected solid segments) were obtained from weighted joinpoint regression analyses of cohort curvatures.
Pastor-Barriuso and López-Abente BMC Cancer 2014, 14:250 Page 9 of 12
http://www.biomedcentral.com/1471-2407/14/250
Pastor-Barriuso and López-Abente BMC Cancer 2014, 14:250 Page 10 of 12
http://www.biomedcentral.com/1471-2407/14/250Joinpoint analyses of period and cohort curvatures
Joinpoint analyses of age-adjusted rates are commonly
used to identify significant trend changes over a given
period. However, with this approach, we are unable to
disentangle whether the observed trend changes across
periods are due to a unique period effect or to an indir-
ect effect induced by birth cohorts [15]. We therefore
conducted weighted joinpoint analyses of the estimated
period and cohort curvatures from the three-factor
model, rather than relying directly on age-adjusted rates.
Although curvatures are hard to interpret in isolation
from the overall linear slopes [22], the locations of
change-points and the associated changes in period
and cohort slopes remain estimable from curvature
components.
Non-Hodgkin’s lymphoma and multiple myeloma
mortality trends
The steady rise in mortality from haematological cancers
until the generations born in the 1920s and the subse-
quent levelling off would suggest that diagnosis and, by
extension, certification of these diseases increase as
health care improves and develops. While there may
feasibly be a strong chance of diagnostic enhancements
[12,13,23] and universal access to health care in Spain
being incorporated into the dramatic increases in NHL
and multiple myeloma rates, it has been argued that
diagnostic improvements cannot fully explain the wide-
spread rise in NHL incidence until the end of the 1990s
in other countries, with the most likely explanation be-
ing an increase in exposure to risk factors [24]. If the
uniform escalation in NHL incidence and mortality oc-
curred due to greater exposure to risk factors of different
nature, then such factors should not only be strongly asso-
ciated with NHL risk, but should also be widely distrib-
uted across all adult age groups, both sexes, and most
developed countries. Severe immunosuppression and cer-
tain infectious agents are the only well-established, strong
risk factors for NHL [24], but these conditions are too in-
frequent in the general population to account for a sub-
stantial part of the widespread rise in NHL rates. Weaker
and less consistent associations with NHL risk have been
reported for occupational and environmental exposures to
chemicals, pesticides, and persistent organic pollutants, as
well as for several dietary and lifestyle factors, including
high intake of fats and meat, overweight, and smoking for
specific NHL subtypes [25]. While exposure to chemicals
and pesticides has mainly been occupational and hence
unevenly distributed between sexes and age groups, the
whole population in developed countries was uniformly
and increasingly exposed to persistent organic pollutants
and unhealthy lifestyle habits during the second half of
the 20th century. The slight but sustained upward period
effects on NHL mortality observed in Spanish men andwomen up to the middle 1990s could be attributable to in-
creased exposure to these potential risk factors, as has
been suggested for NHL incidence in other European
countries [26]. Nevertheless, our results show a more
prominent role of birth cohort, rather than death period,
in defining the dramatic upward trends in NHL and mul-
tiple myeloma mortality in Spain. The sharp rises for earl-
ier generations of both sexes suggest that progressive
improvements in case ascertainment and certification in
the elderly have probably played a major role in the dra-
matic increase in mortality from haematological tumours.
In line with these countrywide mortality findings, previous
studies on NHL incidence trends in several Spanish re-
gions have also reported a recent attenuation of the
long-term epidemic increase in NHL [6,13], which was
mainly attributable to the progressive introduction and
subsequent full implementation of modern diagnostic
procedures.
Hodgkin’s disease and leukaemia mortality trends
As in most Western European countries [3,12,27], mor-
tality from Hodgkin’s disease has declined markedly in
Spain during the last decades, since this neoplasm is
highly amenable to treatment [28]. The continued down-
ward period effects after the middle 1960s, together with
the relatively flat cohort effects, indicate that advance-
ments in the integrated treatment of Hodgkin’s disease
had a favourable impact in all age groups. With regard
to leukaemia, our results are consistent with previous
studies in showing that there has been considerable pro-
gress in its treatment among children and young adults
[4,29], as indicated by the downward trends across pe-
riods and recent generations born after the middle
1960s. However, the favourable effect of leukaemia treat-
ment in young patients was partially offset by the in-
crease in mortality linked to better diagnosis and
certification in earlier cohorts born before the 1920s [3],
thus resulting in an overall levelling off in leukaemia
mortality rates from 1990 onwards.
Male excess mortality from haematological cancers
It is very striking that, despite the markedly different
time trends in mortality from each haematological can-
cer, male-to-female mortality rate ratios remained fairly
constant throughout the entire study period for all
haematological tumours. The male excess mortality per-
sisted not only across successive calendar periods, but also
across all age groups, including children younger than
15 years (see age- and period-specific mortality rates of
NHL and leukaemia in Additional file 2: Video S1 and
Additional file 3: Video S2). The same consistent predom-
inance among men has been reported for NHL incidence
in Spain [13], as well as for the incidence of all four haem-
atological tumours in different countries around the world
Pastor-Barriuso and López-Abente BMC Cancer 2014, 14:250 Page 11 of 12
http://www.biomedcentral.com/1471-2407/14/250[30]. Lifestyle and environmental factors known to be
unevenly distributed between sexes, such as smoking,
alcohol drinking, and occupational carcinogens, can
hardly account for these enigmatic sex disparities in
haematological cancer incidence and mortality [30], giv-
ing way to endogenous sex-specific biological or genetic
factors as a more plausible explanation. The existence
of X-chromosome-linked suppressor factors of haem-
atological tumours has recently been suggested, some-
thing that would help explain the systematic lower
mortality observed in women. In particular, the loss of
the PHF6 tumour suppressor gene, linked to the X
chromosome, has been identified as possibly being in-
volved in the genesis of T-cell acute lymphoblastic leu-
kaemia [31] and adult acute myeloid leukaemia [32],
though neither paper reports the frequency of this dis-
order in the general population. While it is uncertain
whether these findings on very specific types of lymph-
omas and leukaemia could be generalised to other
lymphoid neoplasms and leukaemias, they have already
been observed for some solid tumours [33].
Limitations of the study
Several limitations of the study must be mentioned.
First, we were unable to analyse long-term countrywide
time trends in haematological cancer incidence because
most population-based cancer registries in Spain began
collecting incidence data from 1980 to 1995 and covered
only 26% of the total Spanish population [34]. Neverthe-
less, mortality is a complex indicator that allows asses-
sing both the effect of risk factors on cancer incidence
and the impact of diagnostic and therapeutic advances
on cancer survival. Second, deaths from haematological
cancers were coded according to successive ICD revi-
sions, which are not supported by the new classification
of lymphoproliferative syndromes established in 1995,
known as the Revised European-American Classification
of Lymphoid Neoplasms [35]. Although ICD rubrics for
lymphomas, multiple myeloma, and leukaemia have an
overlap in several cell lines, haematological cancer death
certification in Spain has been shown to be accurate
from 1980 onwards [17]. However, there is no informa-
tion on the quality of death certification in Spain before
1980 and we cannot rule out some degree of under-
certification of haematological cancer deaths in earlier
periods. To evaluate the potential impact of under-
certification on the observed time trends, sensitivity
analyses were performed excluding deaths during the
initial quinquennia 1952-1956 and 1957-1961 and re-
sults remained virtually unchanged (data not shown).
Conclusions
The dramatic increases in NHL and multiple myeloma
mortality observed in Spain during the second half ofthe 20th century are best explained by a cohort effect
linked to progressive improvements in the diagnosis and
certification of these haematological tumours, particu-
larly in the elderly. After full implementation of modern
diagnostic procedures, the recent stabilisations or slight
declines in NHL and multiple myeloma mortality rates
are expected to continue in the near future. In contrast,
the sustained decline in Hodgkin’s disease mortality and
the levelling off in leukaemia during the last decades are
mainly attributable to a period effect linked to advance-
ments in disease treatment. Also, the consistent male ex-
cess mortality across all calendar periods and age groups
points to the importance of possible sex-related genetic
markers of susceptibility in haematological cancers.
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